Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982597 | 0.89 | LMNA (0.44) | LMNASMN1; SMN2L3MBTL1NCOA3MEN1 | |
| SCHEMBL3983664 | 0.86 | LMNA (0.42) | LMNASMN1; SMN2L3MBTL1NCOA3MEN1 | |
| SCHEMBL3988044 | 0.84 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2KMT2AKDM4EMAPT | |
| SCHEMBL3985284 | 0.84 | MEN1 (0.45) | LMNASMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL3983952 | 0.80 | LMNA (0.48) | LMNASMN1; SMN2L3MBTL1NCOA3MEN1 | |
| SCHEMBL4744605 | 0.77 | LMNA (0.45) | LMNASMN1; SMN2L3MBTL1NCOA3MEN1 | |
| SCHEMBL5532677 | 0.77 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2L3MBTL1NCOA3MEN1 | |
| SCHEMBL3985363 | 0.76 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2KMT2AKDM4EMAPT | |
| SCHEMBL4141251 | 0.76 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2L3MBTL1NCOA3MEN1 | |
| SCHEMBL3985780 | 0.75 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | LMNA 3682/4885SMN1; SMN2 4264/4885L3MBTL1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.